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Objective: Todeterminewhether treatmentwithinterleukin-1receptorantagonist(IL1-ra)wouldaffectamniotic
fluid concentrations of tumor necrosis factor alpha (TNF-a) and prostaglandins or clinical or microbiological out-
comes in a model of ascending bacterial infection in pregnancy.
Methods: Timed pregnantNew Zealand white rabbits at 70% of gestationunderwentendoscopicinoculation of
the cervices with 10
6–10
7 cfu Escherichia coli. Animals were randomly assigned in a blinded manner to a 5-h intra-
venousinfusionofhuman IL1-ra(10 mg/kg)orplacebobeginning1–2 hafterinoculation.Bloodwasdrawnfromthe
does for assay of serum IL1-ra concentration before inoculation, at mid-infusion, after the infusion ended and at
necropsy.At necropsy,temperatureandculturesweretaken,andaspiratedamniotic fluid was pooledfor assaysof
TNF-a, prostaglandin E2 (PGE2) and IL1-ra.
Results: SerumIL1-ra concentrationsrosetoa mean of2 mg/ml atmid-infusion andfellmarkedly afterthe infusion
to concentrationsbarely detectable at necropsy.Between the two groups,therewere no significant differences in
the ratesoffeverorpositiveculturesorinamniotic fluid concentrationsofPGE2orTNF-a.Oneuniquefindingwas
thedemonstrationthatadministrationofhuman IL1-ratothedoesresultedinmeasurableconcentrationsofhuman
IL1-ra in the amniotic fluid.
Conclusions: Treatmentwith anintravenousinfusionof human IL1-ra aftercervical inoculation with E.coli did not
affect clinical or microbiological outcomes or amniotic fluid concentrations of TNF-a or PGE2. This experiment
providesthefirstdemonstrationofpassageofhumanIL1-rafromthematernalbloodstreamtotheamnioticfluid.
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Preterm birth and its sequelae remain the leading
perinatal problem in the developed world.
Clinically evident infection such as pyelonephritis
or chorioamnionitis has long been associated with
preterm birth. More recently, research has indi-
cated that subclinical infection is an important
causeofpretermbirthperhapsaccountingforupto
20–40% of cases1. Further, exposure of the pre-
term fetus to bacteria in the intrauterine environ-
ment has been related to adverse neonatal and
childhood outcomes, especially cerebral palsy2.
An overexuberant cytokine cascade may be an
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Clinical Study 233importantlinkbetweeninfection,fetaldamageand
neonatal disease3,4. Our group has recently pro-
vided evidence supporting the hypothesis that an
excess of pro-inflammatory cytokines may cause
fetal damage and neonatal and infant disease5.
In our model of ascending clinical intra-
amniotic infection in the pregnant rabbit, we have
observed that after cervical inoculation with
Escherichia coli, marked increases in amniotic fluid
pro-inflammatory cytokines, tumor necrosis
factor-a (TNF-a) and interleukin-1 (IL-1) a and
b occur as early as 12–16 h after inoculation6.
Increases in these cytokines are accompanied by
increases in prostaglandins E2 (PGE2) and F2a over
thesame time interval. We have also demonstrated
that by 16 h after cervical inoculation with E. coli,
there is placental expression and activation of
nuclear factor-Kappa B (NF-kB), the principal
transcriptional factor that upregulates pro-
inflammatory cytokines5. In the same experiment,
wefoundthattheanti-inflammatorycytokineIL-1
receptor antagonist (IL-1ra) is present in the
placenta and uterus, but does not increase in
responsetoinfectionoverthesame 16-hinterval.
This imbalance in the production of pro-
inflammatory cytokines in response to infection
led us to speculate on the use of IL-1ra as an inter-
vention in this model. IL-1ra blocks the effect of
IL-1 at the cell surface and thus downregulates
pro-inflammatory activity, which in turn results in
reducedproductionofTNF-aand prostaglandins.
Further,animal models have demonstrated benefi-
cial effects of IL-1ra infusions on hemodynamics
afterbacterialchallenge7–9.In thepresentstudy,we
conducted a randomized placebo-controlled trial
to determine whether IL-1ra would affect the
amniotic fluid concentrations of TNF-a and
prostaglandins or clinical or microbiological out-
comes in our model.
SUBJECTS AND METHODS
This protocol was approved by the Animal Care
Committee at the University of Colorado Health
Sciences Center. Timed pregnant New Zealand
white rabbits obtained from an approved vendor
(Myrtle’s Rabbitry, Thompson Station, TN) were
anesthetized on day 21 or 22 of a 30-day gestation
(70%ofgestation).Animalswereanesthetizedwith
intramuscular xylazine (5 mg/kg) and ketamine
(20 mg/kg). After external preparation with
povodone iodine, an endoscope (Storz 27027B,
Karl Storz Endoscopy America Inc., Culver City,
CA) was inserted into the vagina to the cervix, and
a sterile polyethylene cannula was advanced into
the cervix under direct visualization. Through the
cannula, 0.2 ml inoculum containing 106–7 cfu of
E.coliwas injected into eachcervix. E.coli(ATCC
12014) was aerobically inoculated into thiogly-
collate broth and grown for 8 h at 36°C before
concentration and washing. After centrifugation
the pellet was re-suspended in sterile phosphate
buffer and re-centrifuged three times. A final
suspension was then performed to achieve thefinal
concentration. The final concentration was plated
quantitatively before inoculation to confirm
colony count, and an aliquot remaining in each
syringe was plated after inoculation to confirm
viability.
Animals were randomly assigned in a blinded
mannerto a 5-h intravenousinfusion of IL-1ra in a
dose of 10 mg/kg (kindly provided by Amgen
Inc., Boulder, CO) or sterile saline (placebo).
Human IL-1ra was used because a rabbit form was
not available. After inoculation, animals were
observed forupto16 h.Bloodwasdrawnfromthe
doesforassay ofserumIL-1raconcentrationbefore
inoculation, at mid-infusion (2–3 h after the in-
fusion began), after the infusion ended (8–10 h
after the infusion began) and at necropsy.
At necropsy, a rectal temperature was taken.
Cultures were taken from the uterus, amniotic
fluid, peritoneum and blood of the doe by plating
onto MacConkeyand 5% sheep blood agar and by
inoculation into thioglycollate broth. Pooled
amniotic fluid was aspirated for assay of cytokines
and prostaglandins.
TNF-a bioactivity was quantified by one of
the authors (M.P.S.) with an established bioassay
using a mouse fibrosarcoma cell line5. Assays of
serum and amniotic fluid for human IL-1ra were
performed by an enzyme-linked immunosorbent
assay (ELISA) (kindly performed by Amgen Inc.,
Boulder, CO). PGE2 was assayed by a competitive
ELISA (reagents from Cayman Chemical, Ann
Arbor, MI) that uses a monoclonal antibody to
detect PGE2. For this assay, the samples were
diluted in assay buffer and quantified without
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knowledge of the assigned treatment group.
The sample size was calculated based on the
outcomeof fever defined as a rectal temperature of
> 104°F as used in previous experiments in this
model. We anticipated that 60% of untreated
animals would have fever as would 10% of the
treated animals. With alpha = 0.05 and beta = 0.2
and a 2 : 1 treatment to placebo ratio, 26 animals
were needed in the treatment group and 13 ani-
mals in the control group. Categoric data were
analyzed by the Fisher exact test. Continuous data
were analyzed by the Wilcoxon rank sum test,
since assumptions were not met. A p value of
< 0.05 was considered to be significant.
RESULTS
26animalswerestudiedinthetreatmentgroupand
13 animals in the control group. One doe died
during the IL-1ra infusion. This animal was
excluded from the analysis of fever at necropsy.
No animal delivered prior to completion of the
experiment at 16 h after inoculation. The serum
concentrationsofIL-1rain thebloodofthedoesat
various time points are depicted in Figure 1. Con-
centrations rose quickly to a peak at mid-infusion,
fellmarkedlyaftertheinfusionandwere detectable
in only small amounts at necropsy (16 h after
inoculation). None of the placebo group had
detectable concentrations of IL-1ra.
Outcomes are presented in Table 1. Between
the two groups, there were no significant differ-
ences in therates of fever or positive cultures,or in
amnioticfluid concentrationsofPGE2andTNF-a
at necropsy. E. coli was the only organism isolated
from any of the cultures. Amniotic fluid
concentrationsofIL-1raatnecropsyweredetected
only in treated animals. The concentrations found
were similar to those in the maternal serum at
necropsy (range 13.13–86.3 ng/ml). We did not
collect amniotic fluid earlier in the experiment.
DISCUSSION
In the rabbit model of intra-amniotic infection,
treatment with an intravenous infusion of human
IL-1raafter cervical inoculationwithE.colididnot
affect clinical or microbiological outcomes or
amniotic fluid concentrationsof TNF-a or PGE2.
We havedocumentedthematernalserumconcen-
trations of IL-1ra achieved during and after a 5-h
infusion at a dose of 10 mg/kg. We have also
demonstrated that this intravenous infusion of
human IL-1ra into the pregnant rabbit led to
detectableamnioticfluidconcentrationsofIL-1ra.
While these experimental conditions demon-
strated no improvement in outcomes, it would be
prematuretoconcludethatIL-1raisnotapotential
IL-1ra and ascending infection McDuffie et al.
INFECTIOUS DISEASES IN OBSTETRICS AND GYNECOLOGY 235
Figure 1 Serum concentrations of IL-1ra in pregnant
rabbits in relation to a 5-h infusion of human IL-1ra at a
dose of 10 mg/kg. Intervals depicted are pre-infusion,
mid-infusion (2–3 h after infusion began), post-infusion
(8–10 h after infusion began) and necropsy
IL-1ra Placebo p Value
Fever
Positive culture of uterus or amniotic fluid
Any positive culture
Amniotic fluid PGF2 (ng/ml)
Amniotic fluid TNF-a (pg/ml)
Amniotic fluid IL-1ra (ng/ml)
17/25 (68%)
21/26 (81%)
21/26 (81%)
2.98 (0.74SEM)
259.9 (56.8SEM)
14.8 (4.2SEM)
8/13 (62%)
9/13 (69%)
10/13 (77%)
3.55 (0.98SEM)
296.7 (82.0SEM)
ND
NS
NS
NS
NS
NS
IL-1ra, interleukin-1 receptor antagonist; PGE2, prostaglandin E2; TNF-a, tumor necrosis factor alpha; NS, not significant; ND, none
detected; SEM, standard error at the mean
Table 1 Outcomes at necropsy in pregnant rabbits inoculated cervically with Escherichia coli by treatment grouptherapy. First, the dose of IL-1ra was chosen based
on previous work in non-pregnant rabbit models.
It is possible that the concentrations measured in
the serum and amniotic fluid were inadequate to
achieve a clinical effect. The serum concentrations
ofIL-1ra wemeasured at mid-infusion were much
lower than those of Aiura and colleagues8: our
mid-infusion concentration was 2 mg/ml com-
pared with 10 mg/ml in that study. Our assay
measured only human IL-1ra; thus, we cannot
comment on endogenous production of rabbit
IL-1ra. Also, we were unable to measure IL-1 in
serum or amniotic fluid as there currently is no
assay available for measuring this cytokine in the
rabbit.Thus,wecannotcommentonexcess IL-1ra
relative to IL-1. Second, we assessed endpoints
only at necropsy after the infusion had ended. It is
possible that there may have been benefits of
IL-1ra infusion earlier in the course, but that on-
going infection reversed these by the end of the
experiment. Third, it is possible that the human
IL-1ra, though having a homology of approxi-
mately 75% with that of the rabbit, may not have
been effective in this model. Fourth, an inoculum
sizeof106–7cfuineachhornmayhaveproducedso
overwhelming a challenge that an effect of IL-1ra
couldnotbe demonstrated.Fifth,weadministered
IL-1ra intravenously into the maternal compart-
ment,coincidingwiththecompartmentwherethe
E.coliinoculumwas made. Nevertheless, it isposs-
ible that administering IL-1ra intra-amniotically
(perhaps in combination with intravenous admin-
istration) mighthavehad aneffect.Finally, because
we blocked only one pathway of inflammation, it
is possible that other inflammatory cytokines such
as TNF-a or IL-6 may have contributed to the
findings. These points all provide possibilities for
manipulation in future experiments.
We believe additional work with IL-1ra should
be conducted because previous reports supported
the use ofIL-1ra to attenuatetheeffects of sepsis in
animal models, especially the rabbit. Wakabayashi
and colleagues7 developed a model of sepsis in
which rabbits were infused with heat-killed E. coli
to produce shock. These authors demonstrated
that intravenous infusion of 10 mg/kg bolus of
IL-1ra followed by 15 mg/kg per min over 4 h
reduced hypotension and associated leukopenia.
Aiura and colleagues8 infused rabbits with heat-
killed Staphylococcus epidermidis and then treated
rabbits with an intravenous infusion of IL-1ra
10 mg/kg bolus followed by 30 mg/kg per min
over 4 h. Again, IL-1ra blocked a fall in mean
arterial pressure after bacterial infusion compared
with saline-infused controls. Finally, Vallette and
colleagues9 infused live group B streptococci into
newborn piglets and treated them with an intra-
venous infusion of IL-1ra 40 mg/kg bolus
followed by continuous infusion of 60 mg/kg per
min.IL-1ratreated animalshadsignificantly higher
mean arterial blood pressures over time compared
with controls. Because of these successes reported
byothers,webelieve IL-1ra shouldbeevaluated in
additional experimental conditions as an adjunc-
tive therapy to improve outcome in infection-
induced preterm birth.
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